RxDoctor Payments Data

John Allen

Ophthalmology · Morrow, GANPI 1679969935

Payments from drug & device makers

$4,401in general payments, 2019–2025

Across 84 payments — averaging $52.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$891
  • Alcon$827
  • Sun Pharmaceutical Industries Inc.$606
  • AbbVie$437
  • NEW World Medical,inc.$341
  • Bausch & Lomb Americas Inc.$340
  • plus $960 from 13 others

What the payments were for

  • Food & beverage$4,401100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,401 in reported general payments places this provider in the 65th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$365,164
Medicare patients
766
Services billed
3,563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost535$337,897
RocklatanNetarsudil Mesylat/Latanoprost96$74,225
Travoprost308$65,355
CombiganBrimonidine Tartrate/Timolol137$64,935
Latanoprost2,736$37,891
RhopressaNetarsudil Mesylate47$36,983
SimbrinzaBrinzolamide/Brimonidine Tart95$31,495
IlevroNepafenac75$28,014
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol114$27,253
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,442$26,728
RestasisCyclosporine14$18,866
Brinzolamide65$17,957
Alphagan PBrimonidine Tartrate48$17,919
Lotemax SmLoteprednol Etabonate58$15,099
VyzultaLatanoprostene Bunod23$14,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$437$439,616734 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$142$111,208143 claims
AlconSimbrinza$827$31,49595 claims
Bausch & Lomb Americas Inc.Vyzulta$340$14,12923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Morrow

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →